First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Phase III Study Being Initiated For Two-Drug Regimen

 
• By Mandy Jackson
Collection of CT colonography
Amgen boosted responses to Lumakras in colorectal cancer by adding Vectibix to the KRAS G12C inhibitor • Source: Alamy

More from Clinical Trials

More from R&D